Compare NKTR & GOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKTR | GOF |
|---|---|---|
| Founded | 1990 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 1996 | 2006 |
| Metric | NKTR | GOF |
|---|---|---|
| Price | $73.12 | $10.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $130.00 | N/A |
| AVG Volume (30 Days) | 782.4K | ★ 1.6M |
| Earning Date | 03-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $307,711,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 86.00 | N/A |
| 52 Week Low | $0.43 | $10.74 |
| 52 Week High | $77.00 | $15.69 |
| Indicator | NKTR | GOF |
|---|---|---|
| Relative Strength Index (RSI) | 61.90 | 25.14 |
| Support Level | $52.99 | N/A |
| Resistance Level | $75.96 | $15.10 |
| Average True Range (ATR) | 3.59 | 0.17 |
| MACD | -0.63 | -0.02 |
| Stochastic Oscillator | 88.37 | 12.89 |
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.